How international guidelines recommend treating children who have severe COVID‐19 or risk disease progression

Abstract

AbstractAimThis study reviewed the current knowledge and guidelines on managing COVID‐19 in children and proposed a practical approach to drug treatment.MethodsWe analysed international guidelines from four prominent scientific bodies on treating COVID‐19 in children. These were the UK National Institute for Health and Care Excellence, the American National Institutes of Health, the Infectious Diseases Society of America and the Australian National Clinical Evidence Taskforce COVID‐19.ResultsMost paediatric patients with COVID‐19 only require symptomatic treatment. There was limited evidence on treatment recommendations for children with severe COVID‐19 or at risk of disease progression. However, several drugs are available for children and we have summarised the guidelines, in order to provide a concise, practical format for clinicians. All the guidelines agree that nirmatrelvir plus ritonavir or remdesivir can be used as prophylaxis for severe COVID‐19 in high‐risk patients. Remdesivir can also be used for severe COVID‐19 cases. Glucocorticosteroids are recommended, particularly in patients requiring oxygen therapy. Tocilizumab or baricitinib should be reserved for patients with progressive disease and/or signs of systemic inflammation.ConclusionThe guidelines provide useful advice and a degree of consensus on specific drug treatment for children with severe COVID‐19 or at risk of progression.